Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of neoadjuvant intravesical BCG before TURBT in non-muscle invasive bladder cancer
jRCT1061260072Phase 2Recruiting
- Start
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-muscle-invasive bladder cancer (NMIBC) and Bladder cancer in situ (CIS). Primary endpoint: Proportion of grade 3 or higher adverse events during neoadjuvant intravesical BCG instillation therapy. Started Oct 2026; status: recruiting.
02
Conditions
non-muscle-invasive bladder cancer (NMIBC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on jRCT1061260072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260072.